Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.4%

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) dropped 5.4% during mid-day trading on Friday . The stock traded as low as $3.30 and last traded at $3.30. Approximately 1,129,245 shares traded hands during trading, a decline of 30% from the average daily volume of 1,602,089 shares. The stock had previously closed at $3.49.

Analyst Upgrades and Downgrades

AUTL has been the subject of several recent research reports. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Truist Financial lifted their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Trading Down 4.0 %

The company’s 50-day moving average is $3.96 and its two-hundred day moving average is $5.28.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million for the quarter, compared to the consensus estimate of $50.00 million. During the same period in the prior year, the business earned ($0.23) earnings per share. On average, research analysts forecast that Autolus Therapeutics plc will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Cetera Advisors LLC bought a new stake in Autolus Therapeutics in the 1st quarter worth approximately $839,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $108,000. Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $100,000. Price T Rowe Associates Inc. MD grew its position in shares of Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after acquiring an additional 2,487,778 shares during the period. Finally, Avoro Capital Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $78,765,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.